A total of 44 new class 1 drugs have been certified since the launch of the new drug creation special

Medicine network August 2nd, "major new drug creation" national science and technology major special project was launched in 2008, the implementation period is 2008-2020This relationship between the national economy and people's livelihood of the major special officials in that, what is the result? On July 31, the Ministry of Science and Technology, together with the Health and Health Commission, held a major press conference on science and technology on "major new drug creation" in Beijing, introducing the latest progress made in the major special project" new drug creation special output of a number of major landmark results, and achieved significant economic and social benefits"On July 31, the Ministry of Science and Technology, together with the Health and Health Commission, held a major press conference on science and technology in Beijing, said Yang Zhe, deputy director of the Major Special Division of the Ministry of Science and Technology"Since 2017, 14 new class 1 drugs have been approved, showing a blowout growth," said Liu Dengfeng, executive deputy director of the Office of Special Implementation Management of New Drug Creation and Commissioner of the Department of Science and Education of the Health and Health Commission"
1
class of new drugs is 8
times the previoussince the launch of the new drug creation special, China has been approved a total of how many new drugs? "As of July this year, a total of 139 varieties of special drugs have been certified, of which 44 are 1 class of new drugs, the number is 8 times before the implementation of the special projectLiu Dengfeng introduced, in response to the needs of major disease prevention and control, new drug creation special around the industrial chain deployment of research and development chain, major varieties of research and development results are significant, has exceeded the "13th Five-Year Plan" varieties of research and development objectivesnew drugs not only have a large number of varieties, but also very high quality levelsIn the case of anti-tumor drugs, PD-1 immunotherapy-related research won the 2018 Nobel PrizeImmunotherapy is a revolutionary therapy by activating the body's own immune system to fight tumor cells, adapting to a wide range of side effects"Six of the world's top 10 anti-tumor drugs in 2017 were biologicalChina's innovative biological drugs are relatively closer to the international advanced level "New drug creation special technical vice-president Chen Kaixian introduced, since 2018, China has a total of 3 PD-1 inhibitors approved, respectively, Trepri monoantigen, Sindili mono-resistance, Carrie-Zhu mono-resistance "The launch of these PD-1 inhibitor drugs has pushed the country into the era of immunotherapy "
" new drug creation special aimed at foreign medicine frontier Shi Yuankai, vice president of the Oncology Hospital of the Chinese Academy of Medical Sciences, said that since 2018 China has approved the listing of PD-1 drugs, and within six months of the first two foreign PD-1 drugs being approved for listing in China, Chinese companies have independently developed PD-1 drugs, such as ThePridi monoantigen of Junshi Bio and Sindy Li of Sinda Bio "These drugs have given oncology patients in our country new treatment options At present, china has some PD-1/PD-L1 mono-antidote is in clinical trials, it is very worthy of expectation "
some innovative drug development has gone through a long period of time For example, the approval of penicillin in June this year, 30 years ago was included in the national high-tech "863" project to start basic research, the country's 1.1 class of innovative drugs is not easy to come by Wang Yiguang, a researcher at the Chinese Academy of Medical Sciences, said that compensator was safe to take, less oral and low rate of adverse reactions, and had a good effect on bacterial infection sons in the upper respiratory tract At present, the drug has received 16 domestic patents and 41 foreign patents in 16 PCT member countries to promote the cost of medical care greatly reduced
new drug creation special to the people to obtain "accessible and affordable" drugs have played a positive role in promoting Many new drugs fill the domestic clinical gap and promote similar drug prices in the market for example, 80% of liver cancer in China is caused by chronic toxic hepatitis, of which hepatitis C HCV-related accounts for nearly half Danorivi, which was approved for sale in June 2018, is the first direct anti-HCV virus drug developed by local enterprises , and the efficacy is comparable to or even better than that of foreign drugs for the same period, thus reducing the cost of treating hepatitis C patients from $84,000 (about 570,000 yuan) to 40,000 yuan 　　"Since the implementation of the new drug creation special in 2008, in lung cancer, stomach cancer, breast cancer, colon cancer, lymphoma and other treatment drugs have achieved remarkable results, a total of 12 class 1 anti-tumor innovative drugs approved Chen Kaixian said that these anti-tumor innovative drugs on the market to meet the needs of cancer patients in China has made a great contribution many new drugs for the people's actual needs of research and development, better than the efficacy of old drugs, small side effects, can relieve the suffering of the people for example, there are more than 8 million psoriasis (psoriasis) patients in China This type of skin disease is difficult to cure, easy to relapse, to the patient has brought great pain BenVimod cream, which was approved for market at the end of May this year, has shown good results in clinical trials, with better efficacy and safety indicators than the current internationally recognized "golden standard drug" carpotrils The drug was developed by Beijing Wenfeng Tianji Pharmaceutical Technology Co., Ltd., the company's general manager Chen Weihui introduced, the drug is currently in the United States, Japan, Germany and other five countries at the same time to do clinical phase III trials in addition, some new drugs are being targeted in innovation, taking into account the practical application In May 2018, the approved market for injection, Albevetai, developed by Frontier Biopharmaceutical (Nanjing) Co., Ltd., is China's first original new anti-AIDS drug, and the world's first long-acting human immunodeficiency virus (HIV-1) fusion inhibitor Xie Dong, chairman of the company, said that the drug is a long-acting injection drug, once a week, do not have to be like the existing commonanti-AIDS drugs as daily oral This reduces interaction with other drugs, enabling patients with hiv critical conditions who need to treat multiple comorbidities to treat other severe cases at the same time, solving major clinical problems that many surgical patients cannot use After the drug has entered the country's 20 provinces of hospital , China's AIDS prevention and control is of great significance, but also for the global efforts to curb the spread of AIDS has contributed to China's strength the rapid progress of the internationalization process
the creation of new drugs since the start of the special, has produced significant economic and social benefits has promoted the modernization of Traditional Chinese medicine New drug creation special breakthrough in the clinical accurate positioning of traditional Chinese medicine, digital quality control and other core technologies, comprehensively improve the level of Chinese medicine production technology and quality control, accelerate the pace of internationalization of Chinese medicine Up to now, 32 Chinese medicine varieties supported by the creation of new drugs have obtained new drug certificates, 48 varieties have obtained clinical approvals, established 21 modern scientific and technological industrial bases of Chinese medicine, and 4 Chinese and standardized planting bases in the creation of new drugs in the special guidance and support, the process of internationalization of domestic drugs to advance at a high speed By the end of 2018, a total of more than 280 generic drugs registered through Europe and the United States, 29 special support varieties in developed countries in Europe and the United States approved for listing, 23 formulation varieties and 4 vaccine products through the World Health Organization (WHO) pre-certification, more than 100 new drugs to carry out clinical trials in Europe and the United States, a number of self-developed new drugs and high-end preparations to the international special project also made the national drug innovation technology system initially completed Around the different stages of the original innovation and drug research and development chain, a series of technology platforms have been built in the special layout of new drug creation Initial lying to research institutes and universities-based source innovation, enterprise-based technological innovation, close integration of upstream, middle and downstream, deep integration of political, industrial, academic and research grid innovation system, independent innovation ability significantly improved New drug creation special funding results won the national science and technology award 61 items, attracting and gathering a large number of domestic and foreign outstanding senior talent Driven by special traction of new drug creation, China's pharmaceutical innovation investment continues to rise, effectively driving local financial, enterprise and social input, and promoting China's pharmaceutical innovation ecological environment to continuously optimize for the whole of 2018, the pharmaceutical industry achieved a cumulative revenue of 2584 billion yuan, up 12.7% YoY, and a cumulative total profit of 336.45 billion yuan, up 10.9% YoY The cumulative value added of pharmaceutical manufacturing above the scale increased by 9.7% YoY, higher than the overall growth rate of industry by 3.5 percentage points, ranking in the forefront of the industrial industry at present, the number of 10 billion yuan scale pharmaceutical enterprises in China has increased from 2 before the implementation of the special project to 17 Beijing-Tianjin-Hebei, Bohai, Yangtze River Delta, Pearl River Delta and other regions have gradually formed a relatively concentrated, unique biopharmaceutical industry clusters, accelerate regional economic development and industrial transformation and upgrading the special implementation period of new drug creation period from 2008 to 2020, the official in that, how to develop next? "New drug creation special will seriously consider the new positioning and new tasks of China's drug innovation system, and carry out follow-up strategic research." Chen Kaixian said that in the future will strengthen multidisciplinary, multi-technology and methods of convergence, take the initiative to connect the frontiers of science and technology new breakthroughs, open up new directions for new drug research and industrial development, and ultimately to meet the people's "use, affordable" drug needs to contribute